8640 Stock Overview
LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Lixte Biotechnology Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.89 |
| 52 Week High | US$3.52 |
| 52 Week Low | US$1.58 |
| Beta | -0.077 |
| 1 Month Change | 0% |
| 3 Month Change | 9.88% |
| 1 Year Change | -5.03% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -69.52% |
Recent News & Updates
Recent updates
Shareholder Returns
| 8640 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 6.7% | 0.05% |
| 1Y | -5.0% | -1.1% | 9.4% |
Return vs Industry: 8640 underperformed the German Biotechs industry which returned -1.9% over the past year.
Return vs Market: 8640 underperformed the German Market which returned 9% over the past year.
Price Volatility
| 8640 volatility | |
|---|---|
| 8640 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.4% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 8640's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 8640's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 4 | Bas van der Baan | lixte.com |
LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company’s Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma.
Lixte Biotechnology Holdings, Inc. Fundamentals Summary
| 8640 fundamental statistics | |
|---|---|
| Market cap | €5.69m |
| Earnings (TTM) | -€3.90m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.5x
P/E RatioIs 8640 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 8640 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$4.00m |
| Earnings | -US$4.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.78 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 8640 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/12 06:23 |
| End of Day Share Price | 2024/10/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lixte Biotechnology Holdings, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|